Gilead Statement on Settlement Agreement with U.S. Department of Justice Resolving Legacy Compliance Matter

Foster City, Calif., April 29, 2025 – Gilead Sciences has reached an agreement resolving a civil investigation by the U.S. Attorney’s Office for the Southern District of New York concerning the company’s speaker programs from 2011 to 2017 for Gilead’s innovative HIV medicines. 

Gilead entered into this agreement to avoid the cost and distraction of potential litigation regarding this legacy compliance matter. Under the terms of the agreement, Gilead will pay $202 million. 

Gilead’s HIV speaker programs have served to educate healthcare professionals about the appropriate use and benefits of these important medicines. These efforts are important for healthcare providers and patients to have the necessary information to make the best decisions for their care. Gilead’s therapies have transformed the treatment paradigm for HIV, and Gilead will continue to drive innovation to meet patients’ needs. 

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).